• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Pharmacyte Biotech Inc (NQ: PMCB )

    1.890 +0.040 (+2.16%)
    Streaming Delayed Price Updated: 3:58 PM EDT, Aug 14, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 5,294
    Open 1.830
    Bid (Size) 1.890 (17)
    Ask (Size) 1.920 (49)
    Prev. Close 1.850
    Today's Range 1.821 - 1.900
    52wk Range 1.760 - 2.629
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
    From PharmaCyte Biotech, Inc.
    Via Business Wire
    PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q3 2024
    PharmaCyte Biotech just reported results for the third quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    -13.50%
    -13.50%
    1 Month
    -8.25%
    -8.25%
    3 Month
    -9.57%
    -9.57%
    6 Month
    -10.43%
    -10.43%
    1 Year
    -20.92%
    -20.92%

    More News

    Read More
    PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024
    Via InvestorPlace
    PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.
    From PharmaCyte Biotech, Inc.
    Via Business Wire
    Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
    From Femasys Inc.
    Via GlobeNewswire
    PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
    From PharmaCyte Biotech, Inc.
    Via Business Wire
    PharmaCyte Biotech Announces Final Results of Tender Offer
    From PharmaCyte Biotech, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Stocks That Hit 52-Week Lows On Tuesday
    Via Benzinga
    PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share
    From PharmaCyte Biotech, Inc.
    Via Business Wire
    PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan
    From PharmaCyte Biotech, Inc.
    Via Business Wire
    PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital
    From PharmaCyte Biotech, Inc.
    Via Business Wire
    PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation
    From PharmaCyte Biotech, Inc.
    Via Business Wire
    PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study
    From PharmaCyte Biotech, Inc.
    Via Business Wire
    PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study
    From PharmaCyte Biotech, Inc.
    Via Business Wire
    PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022
    From PharmaCyte Biotech, Inc.
    Via Business Wire
    PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells
    From PharmaCyte Biotech, Inc.
    Via Business Wire
    PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value
    From PharmaCyte Biotech, Inc.
    Via Business Wire
    PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego
    From PharmaCyte Biotech, Inc.
    Via Business Wire
    PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value
    From PharmaCyte Biotech
    Via Business Wire
    PharmaCyte Biotech to Implement $10-Million Share Repurchase Program
    From PharmaCyte Biotech, Inc.
    Via Business Wire
    PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites
    From PharmaCyte Biotech, Inc.
    Via Business Wire
    PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes
    From PharmaCyte Biotech, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.